Avidity clamors for $150M raise on heels of positive data readout

And just like other companies, Avidity Biosciences is going for a raise after a positive data readout.

The biotech announced just one day after revealing some positive preliminary data that it was asking investors for $150 million via a public raise. It kept its statement short, saying that it plans to offer the $150 million worth of shares in common stock and give underwriters 30 days to grab an additional 15% on top of what’s in the public offering.